Research
Hormonal
GLP-1 receptor agonists (specifically exenatide) reduce fat mass and energy intake in HO patients but do not significantly alter BMI compared to placebo in the short term, and may decrease total energy expenditure.
Exenatide may help reduce fat mass and waist size in HO, but it often fails to lower BMI significantly. It is not a magic bullet for HO and requires careful monitoring for side effects like nausea.
ModerateQualifiesMEDIUM confidence
Over 36 weeks, BMI increased by 3.5%... with placebo, compared with 1.7%... with exenatide... which was not statistically significant. However, exenatide significantly decreased total body fat mass... and waist circumference.
Why this rating
Based on a single Phase III RCT (ECHO) with modest sample size and non-significant primary endpoint.
Source
Acquired hypothalamic obesity: A clinical overview and update
Christian L. Roth et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15530
narrative_reviewCited 32×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Acquired hypothalamic obesity (HO) is driven by structural damage to medial hypothalamic nuclei (ARC, PVN), leading to hyperphagia, central insulin/leptin resistance, and reduced sympathetic energy expenditure, resulting in rapid, treatment-resistant weight gain.Good
- Setmelanotide (MC4R agonist) is effective in reducing hunger and BMI in patients with HO due to hypothalamic injury, particularly those with specific genetic defects or structural damage affecting the melanocortin pathway.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →